

## **Web accessibility statement**

### **What are we doing?**

We want everyone who visits the Novartis website to feel welcome and find the experience rewarding.

To help us make the Novartis website a positive place for everyone, we've been using the [Web Content Accessibility Guidelines \(WCAG\) 2.0](#). These guidelines explain how to make web content more accessible for people with disabilities, and user friendly for everyone.

We believe that this website meets or exceeds the requirements of the level A criteria of the WCAG 2.0 guidelines.

### **How are we doing?**

#### **Browsers**

This site has been built using code compliant with W3C standards for HTML and CSS. Our website should display correctly in the current and previous two versions of the following browsers: Firefox, Chrome, Internet Explorer, Safari, and Opera.

Our website has also been built to adapt to the screens of the modern mobile devices such as iPhone, iPad, or Android phones.

#### **Text size**

You can vary the text size by using your browser's text resize option: in many web browsers this can be accessed by selecting "View" -> "Text Size" or by pressing Ctrl + and Ctrl - on your keyboard.

#### **Alternative text for images**

All appropriate images have been given alternative text so that reading devices can "understand" them.

## Color contrast

We have checked text and background color combinations to ensure that the contrast is sufficient and we have also ensured that information is not referenced by color alone.

## Exceptions

Whilst Novartis strives to adhere to the accepted guidelines and standards for accessibility and usability, it is not always possible to do so in all areas of the website. We are continually seeking out solutions that will bring all areas of the site up to the same level of overall accessibility. In the meantime should you experience any difficulty in accessing the Novartis website, please don't hesitate to [contact us](#).

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

**Source URL:** <https://www.pro.novartis.com/uk-en/accessibility>